ArticleBMC nephrology2026
IgA nephropathy shortly follwed by seroconversion of positive anti-GBM antibodies and rapid progressive glomerulonephritis in a Chinese boy: coincidental overlap or pathogenic link?
Article in BMC nephrology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAnti-glomerular basement membrane (anti-GBM) disease is a rare, aggressive autoimmune disorder that seldom coexists with IgA nephropathy (IgAN). The development of anti-GBM disease secondary to IgAN in pediatric patients-specifically with confirmed seroconversion-is exceptionally rare. We present a case of a 14-year-old boy who developed anti-GBM disease shortly after an initial diagnosis of IgAN. CASE PRESENTATION: A 14-year-old male presented with a 10-day history of gross hematuria. Initial evaluation showed normal renal function and negative anti-GBM antibodies. The initial renal biopsy confirmed IgAN (Lee grade V; Oxford classification M1E0S1T0-C2). Despite receiving continuous Nefecon monotherapy (16 mg/day) combined with irbesartan 150 mg/day, his renal function deteriorated rapidly four months later, with serum creatinine (Scr) surging from 65 to a peak of 665 µmol/L. Repeat serological testing revealed a significant seroconversion of anti-GBM antibodies from negative to strongly positive (> 8.0 AI). A second renal biopsy demonstrated devastating progression, with 100% fibrocellular crescent formation and intense linear IgG deposition along the glomerular capillary walls. The patient received an intensified regimen consisting of plasmapheresis, hemodialysis, and cyclophosphamide pulse therapy. Following treatment, his anti-GBM antibodies turned negative, and renal function stabilized without dialysis, though it did not return to the pre-morbid baseline.
conclusionsWe report a pediatric male case in whom anti-glomerular basement membrane disease developed secondarily during the clinical course of IgA nephropathy. This case strongly suggests that in patients with newly diagnosed chronic glomerulonephritis, such as IgA nephropathy, a high index of suspicion for concurrent autoimmune diseases including anti-glomerular basement membrane disease should be maintained when rapid progression of glomerulonephritis occurs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.